TABLE 3.
Subgroup analysis of the incidence of all-grade CIPN.
| Subgroup analysis | N | RR (95% CI) | p Values | Test for heterogeneity | ||
|---|---|---|---|---|---|---|
| Chi2 | Ph | I2 | ||||
| Dosage | ||||||
| 300 mg/d | 1 | 0.36 (0.16, 0.83) | 0.017 | — | — | — |
| 600 mg/d | 4 | 0.40 (0.26, 0.60) | <0.001 | 0.54 | 0.909 | 0% |
| 400 mg/d | 3 | 1.03 (0.72, 1.46) | 0.885 | 4.61 | 0.100 | 56.6% |
| Region | ||||||
| Europe | 5 | 0.34 (0.22, 0.53) | <0.001 | 1.00 | 0.910 | 0% |
| America | 1 | 1.21 (0.82, 1.79) | 0.333 | — | — | — |
| Asian | 2 | 0.74 (0.35, 1.60) | 0.449 | 5.40 | 0.020 | 81.5% |
| Blinding | ||||||
| Open-label | 6 | 0.48 (0.27, 0.85) | 0.012 | 26.03 | <0.001 | 80.8% |
| Double-blind | 2 | 0.52 (0.07, 4.06) | 0.531 | 4.45 | 0.035 | 77.5% |
CIPN, chemotherapy-induced peripheral neuropathy; N, number of trials; RR, risk ratio; Ph, p value of heterogeneity.